Selected Publications
Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clin Pharmacol Ther Jan;107(1):171-175, 2020. Review. PMCID: PMC6925644
Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL. Pharmacogenomics. Lancet Aug 10;394(10197):521-532, 2019. PMCID:PMC6707519
Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol 10;(23):2051-2061, 2019 PMCID PMC6804844
Gammal RS, Caudle KE, Klein TE, Relling MV. Considerations for pharmacogenomic testing in a health system. Genet Med Jan 9, 2019. doi: 10.1038/s41436-018-0421-x. Epub ahead of print. PMID:30631112
Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther May;105(5):1095-1105, 2018. PMCID: PMC6576267
Volpi S, Bult C, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Lyman Rodriguez L, Aronson S, Cavallari LH, Denny JC, Dressler L, Johnson JA, Klein TE, Steven Leeder J, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV. Research directions in the clinical implementation of pharmacogenomics - An Overview of US programs and projects. Clin Pharmacol Ther May;103(5): 778-786.doi: 10.1002/cpt.1048, 2018. (PMCID: PMC5902434)
Karol SE, Larsen E, Cheng C, Cao X, Yang W, Ramsey LB, Fernandez CA, McCorkle JR, Paugh SW, Autry RJ, Lopez-Lopez E, Diouf B, Jeha S, Pui CH, Raetz EA, Winick NJ, Carroll WL, Hunger SP, Loh ML, Devidas M, Evans WE, Yang JJ, Relling MV. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia Jun;31(6):1325-1332, 2017. doi: 10.1038/leu.2017.24. [Epub ahead of print] PMID 28096535
Liu Y, Fernandez CA, Smith C, Yang W, Cheng C, Panetta JC, Kornegay N, Liu C, Ramsey LB, Karol SE, Janke LJ, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Yang JJ, Mullighan CG, Zhang J, Evans WE, Jeha S, Pui CH, Relling MV. Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. Clin Pharmacol Ther Jan 16, 2017. doi: 10.1002/cpt.629. [Epub ahead of print] PMID 28090653
Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RR, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV. A Genome-wide Approach Validates that Thiopurine Methyltransferase Activity is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther Aug 26, 2016. [Epub ahead of print] PMID 27564568
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature526(7573):343-50, 2015. PMCID:PMC4711261
Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, Basford M, Bastarache L, Roden DM, Denny JC, Larsen E, Winick N Carroll WL, Cheng C, Pei D, Fernandez CA, Liu C, Smith C, Loh ML, Raetz EA, Hunger SP, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Mattano LA Jr, Relling MV. Genetics of Glucocorticoid-Associated Osteonecrosis in Children with Acute Lymphoblastic Leukemia. Blood126(15):1770-6, 2015. PMCID:PMC4600016
Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV. Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. J Clin Oncol 33(11):1235-42, 2015. PMCID:PMC4375304
Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. Annu Rev Pharmacol Toxicol 55:89-106, 2015. PMCID: PMC4607278
Fernandez CA, Smith C, Yang W, Date M, Bashford D, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Turner V, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Onengut-Gumuscu S, Chen WM, Concannon P, Rich SS, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124(8):1266-76, 2014. PMCID:PMC4141516
Janke LJ, Liu C, Vogel P, Kawedia J, Boyd KL, Funk AJ, Relling MV. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol Jul;183(1):19-25, 2013. PMCID:PMC3702740.
Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119:1658-64, 2012. PMCID: PMC3286344.
Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-91, 2011. PMCID: PMC3098761.
Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 43:237-41, 2011. PMCID: PMC3104508.
Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood December 10, 2010.
Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol April 20, 2010.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med Jun 25;360(26):2730-41, 2009.
Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009.
Yang L, Boyd K, Kaste SC, Kamdem LK, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 27:169-175, 2008.
Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds S, Trevino L, French D, Campana D, Downing J, Evans WE, Pui C, Devidas M, Bowman W, Camitta B, Willman CL, Davies S, Borowitz M, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009.
Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood109:4151-7, 2007.
French D, Wilkinson MR, Yang W, de chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV. Global gene expression as a function of germline genetic variation. Hum Mol Genet 14:1621-1629, 2005.
Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui Ch, Kaste SC. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22:3930-3936, 2004.
Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.
Blanco JG, Dervieux T, Edick M, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH,Relling MV. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343, 2001.
Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001.
Ratain MJ, Relling MV. Gazing into a crystal ball: cancer therapy in the post-genomic era. Nat Med 7:285-287, 2001.
Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Evans WE. Chronic anticonvulsant therapy reduces the efficacy of chemotherapy for childhood acute lymphoblastic leukemia. Lancet 356:285-290, 2000.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999.
Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui C-H. High incidence of secondary brain tumors related to irradiation and antimetabolite therapy. Lancet 354:34-39, 1999.
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualized doses of chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.
Last update: September 2021